Kura Oncology

At Kura Oncology, we are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how we treat cancer. We now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Our pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in four Phase 2 clinical studies: the first is in patients with locally advanced solid tumors that carry HRAS mutations; the second is in patients with peripheral T-cell lymphomas (PTCL); the third in patients with lower risk myelodysplastic syndromes (MDS); and the fourth is an investigator sponsored Phase 2 trial, in patients with urothelial carcinoma tumors characterized by HRAS mutations. Kura’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. Our goal is to help patients with cancer lead better, longer lives.
Type
Public
HQ
San Diego, US
Size (employees)
24 (est)-4%
Kura Oncology is headquartered in San Diego, US

Kura Oncology Office Locations

Kura Oncology has an office in San Diego
San Diego, US (HQ)
125 11119 N Torrey Pines Rd

Kura Oncology Data and Metrics

Kura Oncology Financial Metrics

USD

Net income (Q1, 2017)

(7.5 m)

Market capitalization (25-Jul-2017)

181 m

Cash (31-Dec-2016)

9.7 m
Kura Oncology's current market capitalization is $181 m.
USDFY, 2016

Net Income

(27.6 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

3.3 m3 k3.6 m4 m4.3 m5.2 m

General and administrative expense

1.5 m63 k2.4 m1.8 m1.7 m2.1 m

Operating expense total

4.8 m66 k5.9 m5.8 m6 m7.3 m

Interest expense

(42 k)(42 k)(42 k)(189 k)(194 k)(203 k)

Interest income

22 k38 k114 k124 k131 k128 k

Net Income

(5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.6 k5.6 k15.4 m9.7 m

Accounts Receivable

92.4 m

Inventories

693 k725 k

Current Assets

86.9 m68.8 m

PP&E

71 k40 k

Total Assets

9.1 k5.6 k87.3 m69.8 m

Accounts Payable

3502.4 k4.1 m4.7 m

Current Liabilities

5.1 m5.5 m

Total Liabilities

12.9 m

Additional Paid-in Capital

49.5 k49.5 k108.5 m110.7 m

Retained Earnings

(26.3 m)(53.9 m)

Total Equity

(124 k)(154.7 k)82.1 m56.9 m

Financial Leverage

-0.1 x0 x1.1 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.6 k)(30.7 k)(3.7 m)(27.6 m)

Depreciation and Amortization

1 k31 k

Inventories

(42 k)(32 k)

Accounts Payable

(1.5 k)2.1 k833 k471 k

Cash From Operating Activities

(23.2 k)(16 k)(849 k)(25.3 m)

Purchases of PP&E

(28 k)(64 k)

Cash From Investing Activities

(28 k)12.2 m

Cash From Financing Activities

25 k15 k2 m7.5 m

Interest Paid

352 k
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)

Accounts Payable

8.2 k10.7 k2.5 m3.7 m3.1 m3.3 m4.2 m3.7 m

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials

1

Phase Preclinical

2

Kura Oncology Market Value History

Kura Oncology Company Life and Culture

You may also be interested in